TICKERNERD
Menu
SIONSIONHealthcare · Biotechnology

SION Stock Forecast: Sionna Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.29
−4.17% on the day

The 11 Wall Street analysts covering Sionna Therapeutics, Inc. hold a median 12-month price target of $5.5 — +4.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$239.2M
Ticker Nerd rank
32 / 100
Median analyst target
$5.50
Analysts covering
11
Total return, dividends reinvested
1W
−18.1%
1M
−88.8%
YTD
−87.1%
1Y
−77.7%
From 52W high
−89.6%
From 52W low
+17.6%
$5
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SION stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sionna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
77
Size
66
Revisions
52
Quality
51
Issuance
43
Momentum
40
Value
26
Volatility
24
Growth
9

Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SION stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SION, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26SIONHigh $63.00Median $5.50Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
1 Buy10 Hold0 Sell
Low $5.00Median $5.50High $63.00

The green dot is the last close — the median target sits +4.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026WedbushDowngradeNeutral$53 → $5.00
10 Aug 2026BTIGDowngradeNeutral—
7 Aug 2026GuggenheimMaintainsBuy$50 → $60
26 May 2026CitizensReiteratesMarket Outperform$63
26 May 2026CitizensReiteratesMarket Outperform—
20 May 2026Freedom BrokerDowngradeHold—
20 May 2026Freedom BrokerDowngradeHold$38
18 May 2026StifelMaintainsBuy—
13 May 2026BTIGReiteratesBuy—
5 May 2026WedbushInitiatesOutperform—
28 Apr 2026Jones TradingMaintainsBuy—
27 Apr 2026BTIGReiteratesBuy—
3 Mar 2026GuggenheimMaintainsBuy—
2 Mar 2026BTIGReiteratesBuy—
24 Feb 2026CitizensInitiatesMarket Outperform—
14 Jan 2026BTIGReiteratesBuy—
7 Jan 2026BTIGMaintainsBuy—
23 Dec 2025LifeSci CapitalInitiatesOutperform—
1 Dec 2025RBC CapitalDowngradeUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SION appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SION analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Sionna Therapeutics, Inc. (SION) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.3%

Higher than 26% of US stocks

Return on assets
−21.5%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SION vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SIONSionna Therapeutics, Inc.$239.2M
32
CNXUConexeu Sciences, Inc.$237.9M
2
ABOSAcumen Pharmaceuticals, Inc.$228.2M
44
DTILPrecision BioSciences, Inc.$244.3M
70
GLSIGreenwich LifeSciences, Inc.$244.7M
41
TARAProtara Therapeutics, Inc.$227.5M
36
RNAAtrium Therapeutics, Inc.$225.9M
5

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sionna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SION news & analysis

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

PRNewsWire · 20 Aug 2026negative

Robbins LLP announced it is investigating Sionna Therapeutics to determine whether certain officers and directors violated securities laws or breached fiduciary duties to shareholders in connection with the company's recent stock drop.

Why it matters — The investigation signals potential legal and governance concerns for SION following its recent stock decline, which stockholders may want to monitor.

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 19 Aug 2026negative

Levi & Korsinsky announced a securities investigation into Sionna Therapeutics after the company disclosed that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key sweat chloride endpoint and would not advance the candidate as an add-on therapy. The disclosure led to a roughly 90-92% decline in Sionna's share price.

Why it matters — Sionna watchers would care because the trial failure and resulting share collapse triggered a securities investigation into the company.

Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire · 18 Aug 2026negative

Law Offices of Howard G. Smith announced an investigation into Sionna Therapeutics on behalf of investors concerning possible violations of federal securities laws. The firm is inviting shareholders who suffered losses to contact them about potentially pursuing claims.

Why it matters — A securities fraud investigation signals potential regulatory or legal exposure for Sionna that could affect its standing with investors.

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

Business Wire · 17 Aug 2026negative

The Law Offices of Frank R. Cruz announced a securities fraud investigation into Sionna Therapeutics, Inc. (SION) concerning possible violations of federal securities laws, and is urging investors who lost money to contact the firm. The investigation follows the Company's August 10, 2026, report of topline data.

Why it matters — A federal securities fraud investigation raises the possibility of legal claims and heightened regulatory scrutiny related to the Company's disclosures.

Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information

Business Wire · 17 Aug 2026negative

Robbins LLP announced it is investigating Sionna Therapeutics to determine whether certain officers and directors violated securities laws and breached fiduciary duties to shareholders. The investigation follows a 92% stock plunge to $4.51 on August 10, 2026, after the company reported disappointing results from its Phase 2a proof-of-concept study of SION-719.

Why it matters — A shareholder rights firm is investigating potential securities law violations and fiduciary breaches, which could lead to legal action and further uncertainty for Sionna investors following the sharp stock decline.

FAQ

Frequently asked questions about SION stock

What is the SION stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Sionna Therapeutics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $5 to $63. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SION stock a buy right now?

Of the 11 analysts covering Sionna Therapeutics, Inc., 1 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sionna Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SION?

As at 22 Aug 2026, Sionna Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).

Will SION stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +4.0% from the last close, and Ticker Nerd's factor model ranks Sionna Therapeutics, Inc. 32 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SION stock forecast for 2030?

No analyst covering Sionna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SION are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $63 over the next 12 months.

How has SION stock performed over the past year?

Sionna Therapeutics, Inc. returned -77.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sionna Therapeutics, Inc. do?

Sionna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to address cystic fibrosis, a genetic disorder that impacts the respiratory and digestive systems.

What is the latest news on SION?

The most recent item we track (PRNewsWire, 20 Aug 2026): "Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics". Robbins LLP announced it is investigating Sionna Therapeutics to determine whether certain officers and directors violated securities laws or breached fiduciary duties to shareholders in connection with the company's recent stock drop.

Company

About Sionna Therapeutics, Inc.

Sionna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to address cystic fibrosis, a genetic disorder that impacts the respiratory and digestive systems. The company's primary goal is to advance research and therapeutic approaches that restore the balance of chloride ions, pivotal for treating this life-altering condition. Sionna Therapeutics is dedicated to exploring new treatment avenues by leveraging cutting-edge scientific methods and novel chemical entities. Concentrating primarily on the health and pharmaceuticals sector, the company is part of a niche industry aimed at improving health outcomes for patients with chronic and rare diseases. Sionna Therapeutics plays a crucial role in the healthcare market by targeting unmet medical needs, potentially transforming the lives of those affected by cystic fibrosis. With a commitment to innovation and patient care, the company strives to make significant contributions to the field of genetic medicine.

CEO Mr. Michael Cloonan M.B.A. · 59 employees · United States · https://www.sionnatx.com